Huperzine for Cognitive and Functional Impairment in Schizophrenia

NCT00963846 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: placebo
DRUG: huperzine 0.2 mg BID
DRUG: huperzine 0.4 mg BID
DRUG: huperzine 0.8 mg BID

Sponsor

Biomedisyn Corporation

Collaborators

[object Object]